このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

メタンフェタミン使用障害に対する経頭蓋磁気刺激とエピソード的将来思考のパイロット研究

2026年9月22日 更新者:Heather E. Webber, PhD、The University of Texas Health Science Center, Houston

The purpose of this study is to assess impact of repetitive transcranial magnetic stimulation (rTMS)+Episodic Future Thinking (EFT) vs. sham rTMS+EFT on delay discounting and methamphetamine (MA) demand, on vividness of future positive events during EFT training and on frequency of episodic thinking during the week following EFT training

調査の概要

研究の種類

介入

入学 (実際)

14

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Texas
      • Houston、Texas、アメリカ、77030
        • The University of Texas Health Science Center at Houston

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for primary methamphetamine use disorder
  • Be fluent in English and able to understand the consent form

Exclusion Criteria:

  • Current DSM-5 diagnosis for any illicit substance use disorder other than methamphetamine and marijuana

  • Current DSM-5 diagnosis of moderate or greater severity for alcohol and marijuana use disorder

  • In the opinion of the PI, the presence of any medical, neurological, psychiatric (e.g., psychotic or bipolar disorder), or physical condition, disease, or illness that, may: (a) compromise, interfere, limit, effect or reduce the subject's ability to complete the study; or (b) adversely impact the safety of the subject or the integrity of the data

  • Has current or recent (within 3 months of potential enrollment) suicidal ideation, suicidal behavior, homicidal ideation or a homicidal plan sufficient to raise subject safety concerns based on the following assessments according to the PI:

    1. Structured Clinical Interview for DSM-5 (SCID-5)
    2. Columbia-Suicide Severity Rating Scale (C-SSRS) Screening - Answers YES to Questions 3, 4, 5, or 6
    3. Assault & homicidal danger assessment tool - Key to danger >1
  • Medical implants contraindicating TMS (i.e., aneurysm clips or coils, stents, implanted stimulators, implanted vagus nerve or deep brain stimulators, implanted electrical devices such as pacemakers or medication pumps, electrodes for monitoring brain activity, cochlear implants for hearing, any magnetic implants, bullet fragments, any other metal device or object implanted in your body closer than 30 cm from the coil)

  • History of brain surgery

  • History of an intracranial lesion or any medical or neurological diagnosis/condition associated with increased intracranial pressure (i.e., Idiopathic Intracranial Hypertension/Pseudotumor Cerebri) OR any of the following symptoms within 30 days of enrollment: headaches > 15 days/month, loss of vision or decreased vision

  • Moderate-to-severe heart disease

  • History of stroke

  • Is taking any antidepressant or antipsychotic medication at a dose above the maximum recommended dose or at a dose deemed to be potentially unsafe according to the PI; has taken any of the following medications, which are known to increase the risk of seizures, within 1 week of study enrollment; or does not agree to abstain from taking the following medications during study participation:

    1. clozapine
    2. chlorpromazine
    3. bupropion
    4. clomipramine hydrochloride
    5. amoxapine
    6. maprotiline hydrochloride
    7. diphenhydramine
    8. stimulants other than methamphetamine including the following: Dextroamphetamine and amphetamine, Dextroamphetamine, Lisdexamfetamine dimesylate, Cocaine, Methylphenidate,
    9. tramadol
    10. isoniazid
  • Personal history of epilepsy or seizure disorder and/or family history including a first-degree relative

  • Serious head injury with loss of consciousness

  • Impending incarceration

  • Pregnant or nursing females

  • Inability to read, write, or speak English

  • For adolescent aged participants (18-21 only): any risk factor for neurocardiogenic syncope (history of syncope/presyncope related to noxious stimuli, anxiety, micturition, or posture)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:高周波rTMS+EFT

Participants will identify three personalized and rewarding future events not related to drug use that take place 1 week, 1 month, and 6 months in the future. Participants will be asked to rate the vividness of each personalized future positive event on a 5-pt Likert scale.A brief and personalized EFT prompt will be created for each future event . Personalized EFT prompts will be presented during delay discounting and MA demand assessments following EFT training. Participants will also receive daily text/email messages with these prompts, reminding them to engage in EFT, vividly reexperience their future events, over the week following EFT training.

TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling . For dlPFC, we will measure position F3. The first session will begin with the acquisition of the resting motor threshold on the contralateral hand. Intermittent theta burst stimulation (iTBS) (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the resting motor threshold (RMT) and will last ~3 minutes. Participants will receive 2 sessions of iTBS to the dlPFC brain region with a 15-20-minute interval between sessions

偽コンパレータ:偽rTMS+EFT

Participants will identify three personalized and rewarding future events not related to drug use that take place 1 week, 1 month, and 6 months in the future. Participants will be asked to rate the vividness of each personalized future positive event on a 5-pt Likert scale.A brief and personalized EFT prompt will be created for each future event . Personalized EFT prompts will be presented during delay discounting and MA demand assessments following EFT training. Participants will also receive daily text/email messages with these prompts, reminding them to engage in EFT, vividly reexperience their future events, over the week following EFT training.

Participants will receive sham TMS to the dlPFC. They may feel the TMS from the A/P coil electrodes, but there will not be any real stimulation of the brain.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Rate of delay discounting as assessed by the 5-Trial adjusting Delay Discounting Task
時間枠:before TMS+EFT, after TMS+EFT, 7-day follow-up

This 5 item questionnaire measures the extent to which participants devalue a reward as the delay to its receipt increases.This task presents choices between $500 now vs. $1,000 after a delay.The discount rate k quantifies how rapidly the value of a delayed reward decreases with time.Low k Indicates patience or low impulsivity - greater willingness to wait for larger rewards.High k Indicates impatience or high impulsivity - preference for immediate rewards over delayed ones.

before TMS+EFT, after TMS+EFT, 7-day follow-up
Change in MA Demand as assessed by the Drug Purchasing Task
時間枠:before TMS+EFT, after TMS+EFT, 7-day follow-up

MA demand will be assessed by asking participants how many grams of MA they would purchase to use over the course of a weekend (Friday night to Sunday night) as a function of increasing price ($0 to $10000) Demand is the maximum quantity of Methamphetamine consumed if the drug was free measured in grams or dollar amount

before TMS+EFT, after TMS+EFT, 7-day follow-up
EFT Vividness as assessed by the Vividness Scale
時間枠:measured during EFT training on study day 1

This is a single item questionnaire and is scored on a 5-point Likert scale from 1(not vivid at all) to 5( extremely vivid) for a maximum score of 5, higher score indicating more vivid outcome

measured during EFT training on study day 1
EFT Engagement as assessed by the Engagement Scale
時間枠:7-day follow-up

This is a single item questionnaire and is scored on a 4-point Likert scale 1-4 asking how often each individual engaged in EFT (i.e., every day, most days, some days, no days), higher score indicating more engagement

7-day follow-up

二次結果の測定

結果測定
メジャーの説明
時間枠
タイムラインフォローバック(TLFB)法によって評価されたメタンフェタミン使用日数
時間枠:7日間のフォローアップ
7日間のフォローアップ
タイムラインフォローバック(TLFB)法によって評価された、使用されたメタンフェタミンの量(グラム単位)
時間枠:7日間のフォローアップ
7日間のフォローアップ
Change in prospective memory as assessed by the Prospective and Retrospective Memory Questionnaire (PRMQ)
時間枠:before TMS+EFT, after TMS+EFT, 7-day follow-up

This is a 16 item questionnaire and each is scored on a 5-point Likert scale from 1(never) to 5(very often) for a maximum score of 80, higher score indicating better outcome

before TMS+EFT, after TMS+EFT, 7-day follow-up
Change in prospective memory (PM) as assessed by the behavioral PM task
時間枠:before TMS+EFT, after TMS+EFT, 7-day follow-up

The percentage of correct target identifications on the PM task

before TMS+EFT, after TMS+EFT, 7-day follow-up

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Heather Webber, PhD、The University of Texas Health Science Center, Houston

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年3月31日

一次修了 (実際)

2026年9月15日

研究の完了 (実際)

2026年9月15日

試験登録日

最初に提出

2024年11月26日

QC基準を満たした最初の提出物

2024年11月26日

最初の投稿 (実際)

2024年12月2日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月24日

QC基準を満たした最後の更新が送信されました

2026年9月22日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • HSC-MS-24-0886

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する